Suchergebnisse - "Pinato, David J"

PubPharm (15)

1

Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types : a systematic review

enthalten in: Journal for immunotherapy of cancer | 2024

von Galle, P. | Finn, R. | Mitchell, C. | +4

2

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Alessi, J. | Elkrief, A. | Ricciuti, B. | +25

CommentIn: J Thorac Oncol. 2023 Jun;18(6):682-685. - PMID 37210177

3

A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Chen, M. | Lu, H. | Copley, S. | +7

CommentIn: J Thorac Oncol. 2023 Jun;18(6):686-688. - PMID 37210178

4

Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC

enthalten in: JAMA oncology | 2023

von Rakaee, M. | Adib, E. | Ricciuti, B. | +19

CommentIn: JAMA Oncol. 2023 Jan 1;9(1):60-61. - PMID 36394848

5

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

enthalten in: Cancer treatment reviews | 2022

von Schettini, F. | Venturini, S. | Giuliano, M. | +27

6

Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Takada, K. | Buti, S. | Bersanelli, M. | +13

7

Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC : The Backbone Matters

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Cortellini, A. | Facchinetti, F. | Derosa, L. | +1

CommentOn: J Thorac Oncol. 2022 Jun;17(6):758-767. - PMID 35183773

8

Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma

enthalten in: Expert review of molecular diagnostics | 2022

von Muhammed, A. | D'Alessio, A. | Enica, A. | +6

9

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

enthalten in: Thoracic cancer | 2022

von Banna, G. | Tiseo, M. | Cortinovis, D. | +31

10

Immunotherapy in Hepatocellular Carcinoma

enthalten in: Current treatment options in oncology | 2021

von Fulgenzi, C. | Talbot, T. | Murray, S. | +4